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Abstract
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a serious life-treating
condition characterized by skin eruption, fever, haematologic abnormalities, and multi-organ involvement that can
be fatal if unrecognized, especially in patients with liver failure. Diagnosis may be difficult because it is rarely described
in children and can mimic many different conditions.
Case presentation: We report two cases of DRESS syndrome due to prolonged antibiotic treatment in young children
in whom recovery occurred following different therapeutic approaches. A previously healthy 5-year-old boy had been
receiving intravenous vancomycin for right wrist and left elbow osteomyelitis and developed DRESS syndrome on day
30. The patient achieved a complete resolution of all symptoms with pulse methylprednisolone followed by oral
prednisone. A 4-year-old girl with cystic fibrosis, pancreatic insufficiency, chronic pulmonary colonization by Gram-
positive bacteria admitted for pulmonary exacerbation was treated with intravenous piperacillin-tazobactam and
tobramycin. After 14 days of treatment, she developed DRESS syndrome: antibiotic treatment was therefore stopped,
and without any further therapy, a progressive resolution of the patient’s clinical features was observed within 7 days,
while the normalization of laboratory abnormalities was achieved at 14 days.
Conclusions: Our cases highlight that paediatricians should be aware of the clinical presentations of and therapeutic
approaches for DRESS syndrome, especially in children receiving long-term antibiotic treatment. The removal of the
offending drug is crucial and may be the only life-saving measure. In more aggressive cases, corticosteroid or other
immunosuppressive drugs should be considered to achieve the best outcome.
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Background
Drug reaction with eosinophilia and systemic symptoms
(DRESS) syndrome is a rare, life-threatening, drug-induced
hypersensitivity reaction. Drug hypersensitivity reactions
(DHR) are classified as immediate and non-immediate. Im-
mediate DHRs include urticaria, angioedema and anaphyl-
axis and occur immediately or within the first 6 h after
administration of the drug. Non-immediate DHRs tend to
appear after many days of treatment, with a delayed
T-cell-dependent type of allergic mechanism and DRESS
syndrome is considered as one of this kind of reactions [1].
DRESS is characterized by fever, rash, lymphadenop-
athy, elevated liver enzyme levels, and leukocytosis with
eosinophilia [2]. DRESS syndrome is an uncommon con-
dition with an estimated incidence that varies between
1:1000 and 1:10,000 drug exposures [3]. Furthermore, its
prevalence is higher in adults than in children; therefore,
paediatricians may not be sufficiently aware of this con-
dition [4].
Prompt recognition and adequate management of
DRESS are crucial because its clinical manifestations can
be severe, resulting in a mortality rate of 10% [2]. To
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increase the likelihood of this condition being recognized,
the European Register of Severe Cutaneous Adverse Reac-
tions (RegiSCAR) developed a scoring system based on
clinical findings, the extent of affected skin, the type of
organ involvement and the clinical course to classify
DRESS syndrome as defined, probable or possible [5]. In
this report, we describe two cases of DRESS syndrome
secondary to prolonged antibiotic exposure in young chil-
dren. Our aim is to highlight the possible clinical presen-
tations of this condition, the diagnostic tools to recognize
it and the therapeutic approaches used to treat it in paedi-
atric patients.
Case presentation
Tables 1 and 2 summarize the clinical and laboratory
data for each of the two patients.
Case 1
A previously healthy 5-year-old boy had been receiving
intravenous vancomycin (40 mg/kg/day four times per
day) for 26 days due to right wrist and left elbow osteo-
myelitis. The patient had exhibited clinical and laboratory
improvement. He then suddenly developed a generalized
erythaematous maculopapular and pruritic rash involving
the face, trunk, back and limbs followed by the appearance
of a high-grade fever (up to 40 °C) and weakness. Bilateral
cervical and inguinal enlarged lymph nodes were detected.
Cardio-respiratory and abdominal examinations were
normal. The child also developed facial, neck and scrotal
oedema (Fig. 1).
Laboratory investigations revealed progressive
leukocytosis (26,280/μL, normal value: 4800 − 12,100/ μL)
and eosinophilia (5010/ μL; normal value: 100–500/ μL) on
day 30. Liver function tests showed minimal alterations. In
addition, lactate dehydrogenase (LDH) levels increased to
805 U/L (normal value: 120–300 U/lL. C-reactive protein
(CRP) levels were slightly increased (6.10 mg/dL, normal
value: < 0.5 mg/dL). Coagulation tests also showed alter-
ations and a prolonged international normalized ratio (INR:
1.28, normal value: 0.94–1.22) and an increased d-dimer
(1815 ng/mL, normal value: < 230 ng/ml). Renal function
and electrolytes were normal. Virological examinations (in-
cluding polymerase chain reaction for Epstein-Barr virus,
cytomegalovirus, herpes-simplex virus, hepatitis and parvo-
virus) and autoimmune screening (anti-nuclear, anti-DNA,
anti-neutrophil cytoplasmic, anti-smooth muscle, extract-
able nuclear antigen and anti-mitochondrial antibodies)
were all negative.
A bone marrow aspirate did not show abnormalities,
while a skin biopsy confirmed the presence of eosino-
philic infiltration. Based on the patient’s clinical history
and laboratory findings, the RegiSCAR scoring system
was applied, and the boy was diagnosed with DRESS
syndrome (total score = 7) on day 30. Vancomycin
administration was discontinued and switched to oral
linezolid (10 mg/kg/dose three times per day), which
was interrupted 3 days later as a result of a worsening of
the skin rash and the patient’s general condition. Thus,
pulse methylprednisolone (20 mg/kg/day for 3 days) was
started, resulting in rapid defervescence and prompt
remission of the rash and facial-neck and scrotal edema
within a few days. Oral prednisone (1.5 mg/kg/day) was
continued, and the patient achieved a complete
resolution of all symptoms and normal laboratory tests
within 10 days. Prednisone was gradually reduced and
finally discontinued after 1 month.
Case 2
A 4-year-old girl with cystic fibrosis, pancreatic insufficiency
and chronic pulmonary colonization by Gram-positive bac-
teria was admitted to our hospital for pulmonary exacerba-
tion. Based on the last available sputum culture, intravenous
Table 1 Clinical and laboratory data of the two children with drug reaction with eosinophilia and systemic symptoms (DRESS)
syndrome
ADMISSION DRESS SYNDROME ONSET DIAGNOSIS OF DRESS
SYNDROME
DISCHARGE
Case 1 Case 2 Case 1 Case 2 Case 1 Case 2 Case 1 Case 2
Laboratory data (normal value) Day 1 Day 1 Day 26 Day 14 Day 30 Day 18 Day 40 Day 28
WBC (4800–12,100/μL) 16,650 5600 14,980 8320 26,280 12,140 12,760 7820
Lymphocytes (1500–16,500//μL) 3120 2040 3800 4500 6710 4200 3200 3320
Eosinophils (100–500//μL) 200 220 2330 30 5010 2940 480 440
CRP (< 0.5 mg/dL) 19.59 0.59 3.60 10.31 6.1 3.19 0.03 0.14
AST-ALT (5–36 U/L and 5–29 U/L) 23–22 31–28 34–27 402–62 55–132 1560–311 25–45 36–60
LDH (120–300 U/L) 198 276 779 3637 805 10,880 238 300
PT-aPTT (0.94–1.22 and 0.86–1.20) Not performed Not performed 1.28–1.10 Not performed 1.31–1.06 1.23–1.94 0.98–0.95 0.96–1.03
D-dimer (< 230 ng/mL) Not performed Not performed 1815 Not performed 2000 68,384 120 230
WBC white blood cells, CRP C-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, PT prothrombin time,
aPTT activated partial thromboplastin time
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piperacillin-tazobactam (150 mg/kg/day in three doses) and
tobramycin (10 mg/kg in one dose) were started and re-
sulted in progressive clinical improvement. Daily treatment
with physiotherapy, an inhaled long-acting beta-agonist and
oral pancreatic enzymes was continued throughout the
patient’s hospitalization. After 14 days of treatment, she pre-
sented a high-grade fever (up to 40 °C) and a diffuse
maculopapular erythaematous rash involving the trunk and
eventually the whole body. She also developed generalized
polyadenomegaly as well as hepatomegaly. Laboratory
investigations showed a rise in CRP levels (10.31 mg/dL,
normal value: < 0.5 mg/dL) and a progressive increase in
serum transaminase levels, with aspartate aminotransferase
and alanine aminotransferase levels > 40 U/L and > 10 times
the upper limit of normal, respectively. Coagulation tests
showed very high d-dimer concentrations (68,340 ng/mL,
Table 2 Results of the RegiSCAR scoring system used to diagnose drug reaction with eosinophilia and systemic symptoms (DRESS)
syndrome in two children
Items Patient 1 Score: patient 1 Patient 2 Score: patient 2
Fever≥ 38.5 °C Yes 0 Yes 0
Enlarged lymph nodes Yes 1 Yes 1
Eosinophils a Yes 2 Yes 2
Atypical lymphocytes No 0 No 0
Skin rash > 50% of body surface area Yes 1 Yes 1
Skin rash suggesting DRESS Yes 1 Yes 1
Skin biopsy suggesting DRESS Yes 1 Not applicable 0
Liver involvement Yes 1 Yes 1
Resolution≥ 15 days No -1 No -1
Evaluation other potential causes b Negative 1 Negative 1
Total score 7 6
a: eosinophils 0.7–1.49 × 103/mmc = 1; ≥1.5 × 103/mmc = 2
b: include ANA, blood culture, serology for HVA/ HVB/ HVC, Chlamydia/ Mycoplasma pneumonia, other serology/PCR. None positive and ≥ 3 of the
above negative = 1
Legend: Final score < 2: no case, final score 2–3: possible case, final score 4–5: probable case, and final score > 5: definite case
Fig. 1 Patient 1 with a diffuse maculopapular erythaematous rash involving the face, trunk, back, penis and scrotum (panel a), legs (panel b), and
arms (panel c)
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normal value: < 230 ng/mL), a prolonged activated partial
thromboplastin time ratio (1.94, normal value: 0.86–1.20)
and an INR of 1.23 (normal value: 0.94–1.22). LDH concen-
trations increased to 10,880 U/L at 4 days after the onset of
symptoms. Also in this case, autoimmune, infective and
haematologic tests were negative.
A parallel progressive increase in the patient’s eosinophil
count reached a maximum absolute value of 2940/mmc
on the 18th day. A diagnosis of DRESS syndrome was
established based on a RegiSCAR total score of 6. Anti-
biotic treatment was therefore stopped, and without any
further therapy, a progressive resolution of the patient’s
clinical features was observed within 7 days, while the
normalization of laboratory abnormalities was achieved at
14 days following the onset of DRESS syndrome (the 28th
hospitalization day overall).
Discussion and conclusions
DRESS syndrome is a rare, severe, drug-induced reaction
characterized by a spectrum of systemic manifestations
and multiple organ involvement. Common pharmacologic
triggers for DRESS include aromatic anticonvulsants
(mainly phenobarbital, phenytoin, and carbamazepine),
antibiotics (mainly trimethoprim-sulfamethoxazole, mino-
cycline, vancomycin, and anti-tubercular drugs), dapsone,
allopurinol and nevirapine [6]. However, the list of drugs
that have been associated with the development of DRESS
syndrome is becoming longer and now includes ibuprofen,
acetylsalicylic acid, sulthiame, and griseofulvin as possible
triggers in children [7–10]. The aetiology of DRESS
syndrome is not yet clear, but it has been suggested that
this condition is multifactorial and may include an
immune-mediated hypersensitivity component that is a
direct effect of an interaction between the drugs or their
metabolites and a genetic susceptibility [4]. Furthermore,
an interplay between drugs, viruses (mainly herpes virus 6
[HHV6], but also HHV7, Epstein-Barr virus and
cytomegalovirus) and immune system may have a role as
trigger of DRESS syndrome [11]. In particular, it was
observed that in patients with DRESS and HHV6 reactiva-
tion there was a higher levels of serum thymus and
activation-regulated chemokine (TARC) that would lead
to a Th2-type immune reaction [12]. Moreover, serum
TARC were identified as a marker of severity of inflamma-
tion in drug eruptions [13].
DRESS syndrome typically manifests 2–6 weeks after
the beginning of the administration of the offending drug
[14]. However, early onset at 5 days has been described
[15]. Interestingly, in a recent perspective study, children
treated with antibiotics developed DRESS syndrome after
an average latency of 5.8 days [16]. Fever usually precedes
cutaneous eruption, which generally presents as a diffuse,
pruritic, and macular rash [6, 14]. Furthermore, multiple
organ systems may be involved. Lymphadenopathy is
frequently described as similar to liver involvement and
may progress to liver failure, which is the primary cause of
death in DRESS syndrome [3]. Other systemic involve-
ments include the kidneys, gastrointestinal tract, lungs,
heart and central nervous system. Laboratory abnormal-
ities associated with this condition include leukocytosis
with peripheral eosinophilia, lymphocytosis and
thrombocytopenia. Liver and renal function test results
may also be altered [3, 14]. Because of its highly variable
clinical presentation, other clinical conditions, such as
acute viral infections, hepatitis, sepsis, autoimmune dis-
ease, and haematologic disorders, should be considered in
the differential diagnosis of DRESS syndrome. In our pa-
tients, all the typical signs and symptoms of this condition
(fever ≥38.5 °C, a skin rash extending over more than 50%
of the body surface and lymphadenopathy) developed
more than 14 days after the initiation of intravenous anti-
biotic therapy. Furthermore, both patients progressively
presented typical biochemical abnormalities (eosinophilia
and liver involvement). Atypical lymphocytes were not
detected in our patients, and a skin biopsy was performed
in only the first case. After other potential causes (auto-
immune, infective and haematologic disorders) were ex-
cluded, the RegiSCAR scoring system was used to achieve
a definite diagnosis of DRESS syndrome (total scores of 7
and 6 in cases 1 and 2, respectively; see Table 2).
To treat DRESS syndrome, the offending drug must be
promptly removed. This may be sufficient to achieve the
resolution of clinical and laboratory abnormalities, as we
found in our second case. The pharmacological approach
to treating this syndrome is not completely defined as
such treatments have not yet been evaluated in clinical
trials. Intravenous corticosteroids, administered alone or
followed by oral steroid therapy, have been shown to be
an effective treatment for DRESS syndrome [14, 17, 18].
However, there is no consensus regarding the dose and
route of administration [19]. In our first case, considering
the worsening of the skin rash and the general condition
of the patient after the introduction of linezolid, pulse
methylprednisolone was immediately administered, result-
ing in a rapid clinical improvement. In second patient, a
progressive spontaneous resolution of the clinical features
was observed within 7 days, while the normalization of
laboratory abnormalities was achieved at 14 days following
the onset of DRESS syndrome, highlighting the import-
ance of an early diagnosis to avoid unfavourable outcome.
Of note, different reports have demonstrated an
association of DRESS syndrome with subsequent
autoimmune diseases (i.e., Graves disease, Hashimoto’s
disease, type 1 diabetes mellitus, and autoimmune
hemolytic anemia) [20, 21]. A gradual tapering of
corticosteroid after a starting dose of prednisone of 0.5–
1.0 mg/kg/day may reduce the development of
long-term autoimmune sequelae [22–26].
Castellazzi et al. Italian Journal of Pediatrics  (2018) 44:93 Page 4 of 6
These case reports support the notion that paediatri-
cians should be aware of the clinical presentations of and
therapeutic approaches for DRESS syndrome, especially in
children receiving long-term antibiotic treatment. A
detailed medication history is essential to achieving a
diagnosis. Furthermore, RegiSCAR is a simple and reliable
instrument for confirming a clinical suspicion of DRESS.
The removal of the offending drug is crucial and may be
the only life-saving measure. In more aggressive cases,
corticosteroid or other immunosuppressive drugs should
be considered to achieve the best outcome.
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